Illumina's Wild Ride: AI Hype vs. Market Reality
Update: 2025-10-02
Description
Illumina's Wild Ride: AI Breakthroughs Meet Investor Skepticism! Despite a new AI-powered drug discovery platform and pharma partnerships, Illumina's stock dipped after Barclays reiterated an Underweight rating. Is BioInsight enough to reverse a 25% year-to-date drop and win back wary investors?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
